Navigation Links
Ambit Announces Presentations At The 55th Annual Meeting Of The American Society Of Hematology (ASH)
Date:12/9/2013

SAN DIEGO, Dec. 9, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced four oral presentations given at the 55th Annual ASH Conference in New Orleans, with data highlighting the Company's lead drug candidate, quizartinib. 

Results of the Phase 2b Randomized, Open-Label, Study of Lower Doses of Quizartinib in Subjects with FLT3-ITD Positive Relapsed Acute Myeloid Leukemia (AML): The purpose of this study is to assess the efficacy and safety of lower doses of quizartinib in the treatment of patients 18-years or older with relapsed/refractory FLT3 ITD positive AML to further improve the benefit:risk assessment of quizartinib.

This preliminary analysis is based on data available through May 28, 2013 with a minimum of eight weeks of follow up since the last subject first visit.  A total of 76 patients were enrolled from May 21, 2012 to March 27, 2013.  Median age for all patients was 55 (19-77) and 92% were FLT3-ITD(+).  35 patients remained in follow-up at the time of the analysis, and are currently censored for overall survival.  The following key information was presented:

For dose of 30mg:

  • The CRc rate was 47 percent (5 percent CR+CRp, 42 percent CRi)
  • The rate of HSCT after quizartinib use was 32 percent
  • The median overall survival was 20.7 weeks, with 16/38 patients censored as they remained in follow-up at the time of the analysis
  • Of the 12 patients who were bridged to HSCT, the median overall survival was 31 weeks
  • Grade 2 or greater QT prolongation was 11%, with a 5% grade 3 rate and no grade 4 events
  • For dose of 60mg:

  • The
    '/>"/>

  • SOURCE Ambit Biosciences
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Ambit Announces Participation At Oppenheimer 24th Annual Healthcare Conference
    2. Ambit Biosciences Provides Regulatory Update Following FDA Meeting Regarding Quizartinib (AC220)
    3. Ambit Biosciences to Announce Third Quarter 2013 Financial and Operating Results and Conference Call
    4. Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results
    5. Ambit Biosciences to Announce Second Quarter 2013 Operational Results and Conference Call
    6. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
    7. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
    8. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
    9. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
    10. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
    11. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... IRVINE, Calif. , Oct 22, 2014 ... Irvine, California , announced the receipt ... Small Business Innovation Research award (SBIR) from the National Institute of ... will fund the development of a Pan-HIV Protein Microarray ... the HIV-1 and HIV-2 subtypes and aid in the ...
    (Date:10/22/2014)... , Oct. 22, 2014 Moms are ... health trackers for themselves and their kids, according to ... Report: Health & Fitness Go Mobile for Moms, the ... Series. BabyCenter, the number 1 pregnancy and parenting web ... that 55 percent of moms surveyed say they can,t ...
    (Date:10/22/2014)... PORTLAND, Oregon , October 22, 2014 ... titled, "Global Disposable Gloves Market (Product type, Form, End ... Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation ... the global disposable gloves market. Based on key trends ... to be valued at $7.9 billion by 2020, registering ...
    Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4
    (Date:10/25/2014)... New York, NY (PRWEB) October 26, 2014 ... aesthetic treatments, announces the most advanced and improved laser ... their effective and safe treatments like the lip ... treatments in keeping with specific focus areas of each ... services like cellulite reduction NYC . The company ...
    (Date:10/25/2014)... Background: , In 1998 Bob Savage ... a pioneer in the field of establishing recovery community organizations. ... system and when he retired, he set out to answer ... service. , 1. Where are the people ... , 2. Can the recovery community be organized to ...
    (Date:10/25/2014)... (PRWEB) October 25, 2014 Homeowners that ... has ‘gone bad’ need wonder no more. Clean Crawls ... homeowners should watch out for when it comes to ... according to the article released by Clean Crawls, can ... homeowners that any insulation that has deteriorated, become damp, ...
    (Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, ... sores -- herpes simplex -- might increase the risk of ... fact, being a carrier of certain antibodies to the virus ... "The identification of a treatable cause [herpes simplex] ... lead researcher Dr. Hugo Lovheim, an associate professor in the ...
    (Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, ... that spot increased risks for certain cancers, one might think ... But a new study suggests that, at least with ... out their genes doubled their risk of colon cancer were ... screened. "It didn,t make any difference, not at all," ...
    Breaking Medicine News(10 mins):Health News:BioSkinLaser.Com Now Offers Advanced Medical Aesthetics Procedures 2Health News:BioSkinLaser.Com Now Offers Advanced Medical Aesthetics Procedures 3Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2
    ... of Thailand government. The country’s health minister Mongkol Na Songkhla ... rest of the nation. ,In a conference promoting ... rise at an alarming rate which leads to diabetes and ... said to suffer from diabetes. ,According to him ...
    ... that the same genetic regulator that triggers growth of ... role in the development of the lethal brain cancer ... they showed that knocking out the function of a ... ,The researchers said their findings suggest that targeting ...
    ... rights to commercial companies over clinical and preclinical trial ... medicines and harm public health, says Karin Timmermans of ... PLoS Medicine. ,Writing in a personal capacity, ... to produce generic versions of the "flu drug" oseltamivir ...
    ... a prominent hospital in Toronto for people with chronic diseases ... the Norwalk virus.// ,Diane Whidden, a spokesperson for ... affected. ,The hospital usually has hundreds of patients, ... are 20 active cases only in a capacity of 500-beds. ...
    ... mathematical model of disease cycles developed at the University ... ,Speaking in a symposium titled "New Vistas in ... meeting of the American Association for the Advancement of ... discuss how models that she and coworkers have developed ...
    ... dominated, the retro Sadhana cut and Dev Anand cowlick made ... gurus. ,Hair salons registered up to 75 percent ... spruced up on grooming rituals in preparation for Valentine's Day. ... went for a special hairdo - a crazy and more ...
    Cached Medicine News:Health News:'Gateway' Gene Discovered for Brain Cancer 2Health News:Drug Companies Should Not Have a Monopoly Over Clinical Trial Data 2Health News:Mathematical Model Predicts Cholera Outbreaks 2Health News:Red Ribbons, Curls and Retro Hairstyles Popular on Valentine's Day 2
    Latex agglutination slide test for the qualitative and semi-quantitative in vitro determination of Rheumatoid Factor in serum....
    For the quantitative in vitro determination of Carbon Dioxide in serum and plasma....
    For the quantitative in vitro determination of Uric Acid in serum, plasma and urine...
    The BUN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of urea nitrogen in serum, plasma and urine....
    Medicine Products: